Exploring Sarcopenia in Parkinson's Disease Patients by Combining Serum Biomarker Levels

Parkinson\'s Disease (PD) and sarcopenia are prevalent age-related syndromes, often occurring simultaneously within individuals. Sarcopenia is notably common among PD patients, with severe cases affecting approximately one in every five individuals with PD. Moreover, sarcopenia is closely linked to the accelerated progression of PD, diminished quality of life, heightened mortality risk, and increased susceptibility to falls and fractures. Therefore, early detection of sarcopenia assumes particular significance as it offers an opportunity for interventions aimed at mitigating or delaying muscle degeneration, potentially influencing PD outcomes. This review will delve into the relationship between sarcopenia and PD, methods for screening and testing sarcopenia, and potential avenues for further research and the development of strategies for risk reduction and treatment

NCT Number	NCT06511531
Lead Sponsor	Central South University
Conditions	Parkinson Disease
Enrollment	200 participants
Start Date	2024-08-01
Primary Completion	2024-08-01 (estimated)
Study Completion	2024-09-01 (estimated)
Updated on ClinicalTrials.gov	2024-07-22